Valuation Update With 7 Day Price Move • Jul 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €845, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 13x in the Chemicals industry in Italy. Total returns to shareholders of 28% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €656 per share. 공고 • Jul 13
EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026 EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026, at 10:30 W. Europe Standard Time. Buy Or Sell Opportunity • Jun 30
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 13% to €770. The fair value is estimated to be €637, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.8% per annum. Earnings are also forecast to grow by 5.2% per annum over the same time period. New Risk • Jun 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Buy Or Sell Opportunity • Jun 09
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 15% to €775. The fair value is estimated to be €645, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings are also forecast to grow by 4.7% per annum over the same time period. Buy Or Sell Opportunity • May 22
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to €765. The fair value is estimated to be €633, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.6% per annum. Earnings are also forecast to grow by 4.5% per annum over the same time period. Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • Feb 10
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 15% to €690. The fair value is estimated to be €569, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.8% over the last 3 years. Earnings per share has declined by 3.6%. For the next 3 years, revenue is forecast to grow by 3.4% per annum. Earnings are also forecast to grow by 4.9% per annum over the same time period. Reported Earnings • Feb 08
Full year 2025 earnings released: EPS: CHF19.97 (vs CHF19.70 in FY 2024) Full year 2025 results: EPS: CHF19.97 (up from CHF19.70 in FY 2024). Revenue: CHF1.95b (down 6.7% from FY 2024). Net income: CHF467.0m (up 1.3% from FY 2024). Profit margin: 24% (up from 22% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Chemicals industry in Italy. Board Change • Feb 02
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공고 • Jan 06
EMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Results on Feb 06, 2026 EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 results on Feb 06, 2026 Board Change • Sep 12
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Aug 08
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공고 • Jul 15
EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025 EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025, at 10:30 W. Europe Standard Time. 공고 • Jul 13
EMS-CHEMIE HOLDING AG announces Annual dividend, payable on August 14, 2025 EMS-CHEMIE HOLDING AG announced Annual dividend of CHF 13.9500 per share payable on August 14, 2025, ex-date on August 12, 2025 and record date on August 13, 2025.